Objective. Aberrant neutrophil extracellular trap (NET) formation has been implicated as a mechanism to induce autoreactivity in individuals at risk of autoimmune diseases. The objective of this study was to assess whether medications implicated in cases of drug-induced autoimmunity (hydralazine and procainamide) and medications less commonly associated with drug-induced autoimmunity (minocycline and clozapine) induce NET formation and/or prevent NET degradation.
Objective. Aberrant neutrophil extracellular trap (NET) formation has been implicated as a mechanism to induce autoreactivity in individuals at risk of autoimmune diseases. The objective of this study was to assess whether medications implicated in cases of drug-induced autoimmunity (hydralazine and procainamide) and medications less commonly associated with drug-induced autoimmunity (minocycline and clozapine) induce NET formation and/or prevent NET degradation.
Methods. Human neutrophils were incubated with the drugs of interest and resultant NET formation was quantified by fluorescent microscopy. The ability of these drugs to interfere with NET degradation by serum nuclei was assessed. Pathways of drug-induced NET formation were studied with pharmacologic inhibitors of reactive oxygen species (ROS), peptidylarginine deiminases (PADs), and muscarinic receptors, and by assessment of intracellular calcium levels by flow cytometry. To determine if NET protein cargo varies by drug stimulus and/or neutrophil source, proteomic analysis of NET lysates induced by specific medications was compared using neutrophils from healthy donors and from patients with autoimmune diseases.
Results. Hydralazine and procainamide significantly induced NET formation while minocycline and clozapine did not. None of the medications significantly impaired NET degradation. NETosis induced by these drugs required NADPH oxidase and PAD4 activation. Procainamide triggered NETs via muscarinic receptor engagement on neutrophils, while hydralazine modulated calcium release from intracellular stores. Differences in protein cargo, particularly histone content, were observed in NETs induced by hydralazine and procainamide.
Conclusion. Medications commonly implicated in drug-induced autoimmunity trigger NET formation displaying distinct protein cargo, via common and specific pathways. NETosis may play a role in the pathogenesis of drug-induced autoimmunity.
Drug-induced autoimmunity is an immune-regulated adverse effect that is triggered by exposure to specific medications. Clinical features of drug-induced autoimmunity include multisystem organ disease associated with production of various autoantibodies, particularly antinuclear antibodies (ANAs) and antineutrophil cytoplasmic antibodies (ANCAs). The pattern of autoantibody production and organ system involvement often mirrors clinical features otherwise specific to systemic lupus erythematosus (SLE) or ANCA-associated vasculitis (AAV). Among the list of medications implicated in drug-induced autoimmunity, procainamide and hydralazine are considered high risk for the development of autoimmunity (1) . Procainamide is associated with development of ANA in almost all patients with long-term exposure to the drug, and symptoms of a lupus-like syndrome develop in~20% of these patients (2) . Approximately 5% of patients exposed to hydralazine develop autoimmune disease, often characterized by overlap features otherwise seen in idiopathic SLE and AAV (2, 3) . Cases of drug-induced lupus or vasculitis have been reported in association with use of minocycline or clozapine; however, these medications carry substantially lower risk to induce autoimmunity compared to hydralazine or procainamide (3) .
Neutrophil extracellular traps (NETs) are web-like structures comprising nuclear DNA and cytosolic proteins that are extruded from neutrophils in response to specific sterile and non-sterile stimuli (4) . Enhanced NET formation and impaired NET degradation have been implicated in the pathogenesis of SLE and AAV (5). Specific contents of NETs include double-stranded DNA, histones, myeloperoxidase (MPO), and proteinase 3, which are the major antigenic targets of autoantibodies detected in AAV, SLE, and drug-induced autoimmunity. Certain medications linked to drug-induced autoimmunity are known to trigger NET formation. Propylthiouracil, a thyroid medication associated with drug-induced AAV, can induce NET formation and impair NET degradation (6) . Levamisole, an antihelmintic drug, can induce autoimmunity in people inadvertently exposed to the drug via contaminated cocaine; additionally, it can trigger NET formation via stimulation of muscarinic receptors on the surface of neutrophils, and the resultant NETs are toxic to vasculature (7) .
We undertook this study to profile the effect of procainamide, hydralazine, minocycline, and clozapine on NET formation, NET degradation, and NET protein content. The study rationale was to demonstrate that certain medications causally linked to drug-induced autoimmunity enhance NET formation, providing additional evidence that neutrophils and NETs are involved in the pathogenesis of specific drug-induced and idiopathic autoimmune diseases.
MATERIALS AND METHODS
Human subjects. Healthy volunteers were recruited from the National Institutes of Health Blood Bank. Patients with a diagnosis of AAV or SLE were recruited from disease specialty clinics within the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Patients with AAV or SLE fulfilled respective classification criteria (8, 9) and were studied during a period of clinical remission. All patients provided written informed consent, and samples were collected according to human subject protocols approved by the NIAMS Institutional Review Board.
Neutrophil isolation and stimulation. Neutrophils were isolated from heparinized blood over a density gradient as previously described (10) . Red blood cells were lysed with hypertonic solution, and neutrophils were resuspended in neutrophil medium (RPMI 1640; Life Technologies). Isolated neutrophils (1 9 10 6 cells/ml) were stimulated with 50 nM phorbol myristate acetate (PMA) and with drugs across a range of concentrations including physiologic concentrations when administered to humans: hydralazine (10 lM), procainamide (40 lM), clozapine (0.8 lM), or minocycline (8.5 lM) (all reagents from Sigma-Aldrich). These neutrophils were subsequently incubated in poly-L-lysine-coated coverslips for 4 hours at 37°C. Pathways of NET formation were studied by pretreating neutrophils with 10 lM diphenyleneiodonium chloride (DPI) (NADPH-oxidase and mitochondrial reactive oxygen species [ROS] inhibitor) for 10 minutes, with 200 lM Cl-amidine (peptidylarginine deiminase [PAD] inhibitor) for 15 minutes, or with 100 lM tetramethylbenzidine 8 (TMB 8) (intracellular calcium antagonist) for 15 minutes. To assess cholinergic receptor involvement, neutrophils were pretreated with a generic muscarinic receptor antagonist (100 lM atropine) or with antagonists to specific muscarinic subtype receptors for 10 minutes: 100 nM telenzepine (type 1 muscarinic receptor [M 1 ] antagonist), 2.5 lM methoctramine (M 2 receptor antagonist), or 12.5 lM 4-damage associated molecular pattern (DAMP) (M 3 receptor antagonist). Telenzepine and 4-DAMP were obtained from Tocris. Atropine and methoctramine were obtained from Sigma-Aldrich.
NET degradation assay. Neutrophils from healthy donors were resuspended at 1 9 10 6 cells/ml, treated with 2.5 lM calcium ionophore (A23187) or 500 nM PMA, procainamide, hydralazine, minocycline, or clozapine, and seeded in coverslips for 4 hours at 37°C. Since positively charged residues on hydralazine or procainamide could potentially bind to DNA and prevent NET degradation, an additional dose of the medications was added after 4 hours, to test whether direct interaction between druginduced NETs and the drugs themselves also contributed to the rate of NET degradation. Drug-induced NETs were exposed to 1% serum from healthy donors and incubated for 16 hours at 37°C. After incubation, the cells were fixed with 4% paraformaldehyde and the degree of NETs was quantified by fluorescence microscopy as described below.
Visualization and quantification of NETs by fluorescence microscopy. Neutrophils, seeded in coverslips, were fixed with 4% paraformaldehyde. Cells were stained with anti-MPO (1:1,000; Dako), Hoechst 33342-conjugated DNA (1:1,000; Life Technologies), as well as Alexa Fluor 555-conjugated donkey anti-rabbit IgG as secondary antibody (1:400; Life Technologies). After mounting (Prolong; Life Technologies), cells were visualized using a Leica DMI 4000B fluorescence microscope. Images were loaded onto Adobe Photoshop, and NET formation was quantified at 409 magnification by counting the percentage of neutrophils undergoing NET formation averaged over 4 fields of view. NETs were identified as extracellular structures positive for both MPO and DNA.
Calcium release and influx measurements using Indo 1-AM. Neutrophils isolated from healthy volunteers were resuspended in a Ringer's solution and loaded with Indo 1-AM (Life Technologies) by incubation with 2.5 lM Indo 1-AM for 30 minutes. The cells were then washed and resuspended in RPMI and 10% fetal bovine syndrome. Immediately prior to the experiment, the cells were resuspended in warm calcium-free media containing NaCl (140 mM), KCl (5 mM), MgCl 2 (1 mM), HEPES (10 mM) (pH 7.4 with NaOH), glucose (10 mM), and EGTA (0.2 mM). Indo 1-AM fluorescence was measured using an LSR Fortessa (BD Biosciences). Calcium levels were quantified as the ratio of bound violet (BUV 395):free blue (DAPI). Baseline calcium levels were measured for 1.5 minutes. Cells were stimulated with 10 lM hydralazine or 40 lM procainamide to test for calcium release from intracellular stores. The sarcoplasmic/endoplasmic reticulum (Ca2+ATPase) inhibitor thapsigargin (1 lM) was used as a positive control to induce calcium release. Data were collected for 1-5 minutes after addition of each compound. The resulting data were analyzed using FlowJo version 9.9.3. At least 4 independent experiments were performed per condition.
Toll-like receptor (TLR) ligand screening. Activation of TLRs can trigger NET formation. Because the chemical structures of hydralazine and procainamide resemble nucleotides, TLR ligand screening (InvivoGen) was performed according to manufacturer recommendations (http://www.invivogen.com/cus tom-tlr-screening) to assess whether hydralazine or procainamide activates TLR pathways. Screening was performed using a panel of HEK 293-TLR-Blue clones engineered to express only a single specific TLR and a secreted enhanced alkaline phosphatase (SEAP)-reporter plasmid, activated with NF-jB. Cells incubated with TLR-specific ligands were used as a positive control. Cell activation was evaluated as an increase in SEAP activity measured as absorbance at optical density of 650 nm, using QuantiBlue reagent according to the protocol of the manufacturer (InvivoGen).
Proteomic analysis of NETs. To determine if specific drugs can affect the contents of NETs, neutrophils isolated from 5 healthy donors were stimulated with procainamide, hydralazine, or 5 lg/ml of lipopolysaccharide, and the protein content of the resultant NETs was compared across stimuli. Since most healthy people do not develop drug-induced autoimmunity when exposed to hydralazine or procainamide, genetic susceptibility factors may influence the contents of drug-induced NETs. To model potential additional susceptibility factors, neutrophils prone to NETosis were isolated from 4 patients with SLE and 4 patients with AAV during clinical remission and stimulated with procainamide or hydralazine, or allowed to generate spontaneously in the absence of additional stimuli. NET lysates were isolated as previously described (11) . For each stimulation experiment, NET proteins in a standardized concentration were sent for proteomic analysis to the Protein Characterization Laboratory, Frederick National Laboratory for Cancer Research (Frederick, MD).
Statistical analysis. All statistical analyses were performed using GraphPad Prism version 6. Differences in distributions were compared using the Kruskal-Wallis test with Dunn's post hoc test for group comparisons, or the MannWhitney U test for pairwise comparisons. For the proteomics data, spectral counts were considered equivalent to protein counts and were compared across groups using one-way analysis of variance, and P values were adjusted using Bonferroni correction for multiple testing. P values less than 0.05 were considered significant for all experiments except the proteomic analyses, in which P values less than 0.002 defined statistical significance.
RESULTS
Procainamide and hydralazine trigger NET formation. Neutrophils were treated with procainamide, hydralazine, clozapine, and minocycline. After 4 hours of stimulation, procainamide and hydralazine induced significant NET formation when compared to unstimulated conditions, whereas clozapine-and minocyclineinduced NET formation was not significant (Figures 1A  and B) . To address whether drugs that induce NETs also impair NET degradation, drug-induced NETs were exposed in vitro to 1% serum from healthy volunteers for 16 hours. In each experiment, sera significantly degraded NETs with no differences observed when comparing induction with the calcium ionophore A23187 (known to induce NET formation) (12), hydralazine, or procainamide ( Figure 1C ). Stimulation with minocycline or clozapine or addition of another dose of the drugs after the 4-hour stimulation did not result in protection of NETs against subsequent degradation (data not shown). These results indicate that procainamide and hydralazine promote NET formation without interference with NET degradation.
Dependence of procainamide-and hydralazineinduced NET formation on ROS and PAD4 activation. In order to investigate whether induction of NETs by procainamide or hydralazine was dependent on formation of ROS and activation of PAD4, neutrophils were pretreated with DPI and the pan-PAD inhibitor Cl-amidine, respectively. NET formation induced by procainamide or hydralazine was significantly inhibited in the presence of DPI and Cl-amidine (Figure 2A) , implicating the production of ROS and activation of PAD4 in drug-induced NETosis.
Activation of PAD4 is a calcium-dependent process, and hydralazine can modulate intracellular calcium levels in cardiac myocytes (13) . We therefore investigated whether stimulation with hydralazine or procainamide causes neutrophils to release calcium from intracellular stores. In calcium-free media, intracellular calcium levels rapidly and transiently increased upon exposure of neutrophils to hydralazine or thapsigargin (P < 0.05 for maximum calcium peak, compared to background). Exposure of neutrophils to procainamide resulted in a slower nonspecific rise in intracellular calcium levels that did not significantly differ from background ( Figure 2B ). Inhibition of intracellular calcium release with TMB 8 significantly abrogated hydralazine-induced NETosis ( Figure 2C ). These results demonstrate that hydralazine induces calcium release, which provides a mechanism for hydralazine-induced PAD4 activation.
Since NET formation can be initiated by stimulation of different membrane and intracellular neutrophil receptors, we investigated whether procainamide or hydralazine could induce TLR activation. Screening analysis showed that procainamide and hydralazine did not stimulate any human TLRs ( Figure 2D ). Levamisole, a known cause of drug-induced autoimmunity, can trigger NET formation via engagement of muscarinic receptors on the surface of neutrophils (7). NETs induced by procainamide, 
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but not by hydralazine, were inhibited by atropine (nonspecific muscarinic receptor antagonist) and by M 1 /M 3 muscarinic subtype receptor antagonists ( Figure 2E ). These findings indicate that procainamide engages neutrophil muscarinic receptors to trigger NET formation.
Distinct protein cargo in the NETs induced by procainamide and hydralazine. Since hydralazine and procainamide induced NETs via different mechanisms, we assessed whether specific drug stimuli could influence specific NET contents. The protein content of NETs induced by procainamide or hydralazine was studied using neutrophils from healthy donors ( Figure 3A ). There were no significant differences among neutrophil proteins originating from the nuclear, cytosolic, or cytoskeletal compartments in terms of their levels of expression on NETs. Among granular proteins, NETs induced by hydralazine contained significantly more azurocidin and less lactoferrin compared to NETs induced by procainamide, but there was considerable variability among samples.
Greater differences in protein content of NET cargo were observed in neutrophils from patients with autoimmune diseases (Figures 3B and C) . The most significant differences were seen among nuclear proteins externalized in NETs. Patterns of histone abundance depended upon both the stimulus (spontaneous, hydralazine, or procainamide) and the underlying disease (SLE, AAV). Of the cytosolic proteins, S100 calcium binding protein A9 (S100A9), S100A8, and S100A12 were all differentially expressed in drug-induced NETs compared to spontaneous NETs. With regard to cytoskeletal proteins externalized in NETs, differential expression of a-actinin, filamin A, myosin 9, plastin 2, and vimentin depended again on the stimulus and underlying disease. In the granular compartment, significant differences were observed for lactoferrin and MPO. Notably, higher amounts of MPO were observed in spontaneous NETs isolated from patients with AAV or SLE.
Comparison of NET contents in patients with AAV versus those with SLE revealed significantly greater amounts of lactoferrin, H2A, S100A8, and S100A9 in NETs from unstimulated neutrophils from patients with SLE, and significantly greater MPO, H2B, H4, and Figure 3 . Procainamide and hydralazine induce neutrophil extracellular traps (NETs) composed of distinct proteins. Differences in NET protein cargo (granular, nuclear, cytosolic and cytoskeletal) in neutrophils from healthy controls (n = 5) (A), patients with antineutrophil cytoplasmic antibody-associated vasculitis (AAV) (n = 4) (B), and patients with systemic lupus erythematosus (SLE) (n = 4) (C) exposed to lipopolysaccharide (LPS), procainamide (Pro), hydralazine (Hyd), or no additional stimuli were assessed. Values are the mean AE SD. * = P < 0.05; ** = P < 0.01; *** = P < 0.001; **** = P < 0.0001 by two-way analysis of variance without correction for multiple comparisons. After Bonferroni correction for multiple comparisons, P values less than 0.002 were considered significant. MMP-9 = matrix metalloproteinase 9; MPO = myeloperoxidase; NGAL = neutrophil gelatinase-associated lipocalin; PR3 = proteinase 3.
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IRIZARRY-CARO ET AL S100A12 in NETs from unstimulated neutrophils from those with AAV. With respect to histones, stimulation with procainamide or hydralazine resulted in significantly greater amounts of H2B, H3, and H4 in patients with SLE versus those with AAV. Amounts of H2A in neutrophils from patients with AAV were significantly higher after stimulation with hydralazine, whereas H2A levels in neutrophils from patients with SLE were significantly higher after stimulation with procainamide.
DISCUSSION
NETosis is a distinct form of neutrophil cell death that differs morphologically from apoptosis, necrosis, and other types of cell death. The extent of the stimuli that can trigger NET formation and the subcellular events of NETosis remain to be fully elucidated. The present study expands the list of medications known to induce NETs. Procainamide and hydralazine, 2 medications definitively implicated in cases of drug-induced autoimmunity, trigger NET formation, while minocycline and clozapine, 2 medications less commonly implicated in drug-induced autoimmunity, do not. These observations, in combination with the previously reported associations of propylthiouracil (6) and levamisole (7) with NETosis, strongly suggest that NETosis is involved in the pathogenesis of drug-induced autoimmunity, possibly through the externalization and modification of intracellular autoantigens.
A few cellular events are considered important in NET formation, namely, the production of ROS and histone modifications mediated by PAD enzymes (5) . The generation of superoxide by the NADPH oxidase process is a critical step in procainamide-or hydralazine-induced NET formation. PAD4 activation, a calcium-dependent process, mediates citrullination of histones, which promotes chromatin decondensation. Inhibition of PADs abrogates NET induction by procainamide and hydralazine.
Modulation of calcium flux is a known trigger of NETosis, and both calcium ionophore and thapsigargin can induce NETs (12) . Although the precise mechanism of action remains unknown, hydralazine is thought to function as an antihypertensive medication, altering the calcium balance within vascular smooth muscle cells (13) . Short-term exposure of neutrophils to hydralazine resulted in a transient increase in intracellular calcium levels that mirrored the kinetics of thapsigargin-induced calcium flux, and calcium antagonists inhibited hydralazine-induced NETosis. These findings suggest that hydralazine triggers NET formation in part by triggering calcium release from intracellular stores.
The present study provides additional evidence that cholinergic receptors can affect neutrophil function.
We previously demonstrated that neutrophils possess muscarinic receptors that can be activated by acetylcholine or levamisole to induce NET formation, and that surface cholinergic receptors are more abundant in neutrophils from patients with SLE (7) . In this study, we have shown that procainamide also triggers muscarinic receptors on neutrophils to promote NETosis. Procainamide, an antiarrhythmic agent, blocks sodium channels but can interact with muscarinic receptors (14) . These findings suggest that the cholinergic properties of specific medications may contribute to the risk of drug-induced autoimmunity.
The present results further demonstrate that protein content within NETs varies by source of stimulation and by source of donor neutrophils. In a previous study using similar methodology, NET protein content differed when neutrophils from healthy donors were stimulated with rheumatoid arthritis-associated autoantibodies versus various cytokines (11) . In the present study, there were only a few differences in NET content when neutrophils from healthy donors were stimulated, and greater differences when neutrophils from patients with AAV or SLE were tested. Because most patients who are exposed to medications associated with drug-induced autoimmunity do not develop overt signs of autoimmunity, additional susceptibility factors are likely involved. Although we did not directly investigate neutrophils from patients with drug-induced autoimmunity (a limitation of the current study), we did observe differences in NET content when specific medications were used to stimulate NETosis-prone neutrophils from patients with other autoimmune diseases. External factors (e.g., environmental exposures to certain medications) and intrinsic host factors (e.g., donor source of neutrophils) may both contribute to disease susceptibility in patients with drug-induced autoimmunity.
Further investigation is warranted to determine whether patterns of disease-associated autoantibodies or clinical features of drug-induced autoimmunity are influenced by the protein content of NETs. In addition to differences in protein abundance within NETs, posttranslational modification of proteins during NETosis and drug-protein adduct effects may contribute to pathogenesis of druginduced autoimmunity and should be explored in future studies. Historically, investigations into the mechanisms of drug-induced autoimmunity have focused upon the effects of specific medications on the adaptive immune system. Inhibition of DNA methylation in T cells has been proposed as a potential underlying mechanism of druginduced autoimmunity (15) . Whether epigenetic modifications of neutrophils contribute to drug-induced autoimmunity warrants investigation.
The present study demonstrates that neutrophils, in addition to mononuclear cells, may contribute to drug-induced autoimmunity. Medications commonly implicated in drug-induced autoimmunity can trigger NET formation through common and specific pathways. Elucidating the mechanisms of drug-induced autoimmunity may provide key insights into causal factors of autoimmunity.
